Add Company
Join Now

Bold Therapeutics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Bold Therapeutics's estimated annual revenue is currently $3.4M per year.(i)
  • Bold Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Bold Therapeutics has 22 Employees.(i)
  • Bold Therapeutics grew their employee count by 29% last year.

Bold Therapeutics's People

NameTitleEmail/Phone
1
President and CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.8M4920%$40MN/A
#2
$0.2M20%N/AN/A
#3
$1.6M21-12%N/AN/A
#4
$3.4M2229%N/AN/A
#5
$13.5M875%N/AN/A
#6
$2M268%$89.5MN/A
#7
$2.8M180%N/AN/A
#8
$49.1M31721%N/AN/A
#9
$1.1M70%N/AN/A
#10
$0.8M525%N/AN/A
Add Company

What Is Bold Therapeutics?

Bold Therapeutics is a clinical stage biotechnology company developing a first-in-class cancer therapy for the treatment of gastric, pancreatic, colorectal and other cancers in combination with existing anti-cancer therapies.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Bold Therapeutics News

2022-04-19 - Gastric Cancer Market Trends Analysis, Clinical Activities ...

... Clinical Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies – RemeGen, Innovent Biologics, Bold Therapeutics,...

2022-04-06 - BOLD-100's Broad Potential Featured at the AACR Annual ...

VANCOUVER, BC, April 6, 2022 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be...

2022-04-06 - Bold Therapeutics Selected as 2nd Place Winner at 2022 ...

Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR)...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M220%N/A
#2
$2.2M220%N/A
#3
$3.4M22120%N/A
#4
$2.3M22-8%N/A
#5
$3.8M2247%N/A